[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fTjq9zxTfgiFyibBKs22Q8icNv54kJFA71SlbRB6RsMk":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":79,"rows":86},"Sir Mortimer B. Davis - Jewish General Hospital",[4],61,false,26,13,21092,12,32,[14,17,20,23,25,27,29,31],{"name":15,"count":16},"Prostate Cancer",17,{"name":18,"count":19},"Erectile Dysfunction Following Radical Prostatectomy",3,{"name":21,"count":22},"Deep Venous Thrombosis",2,{"name":24,"count":22},"Rectal Cancer",{"name":26,"count":22},"Cancer",{"name":28,"count":22},"Post-Thrombotic Syndrome",{"name":30,"count":22},"Metastatic Prostate Cancer",{"name":32,"count":22},"COVID-19",[34,39,44,49,54,59,64,69,74],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT05257629","Aggressive Smoking Cessation Trial (ASAP)","2026-03-07","Combination Therapy Arm",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT06530524","Pretreatment Botulinum Toxin in Head and Neck Cancer Surgery","2026-10-01","OnabotulinumtoxinA",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT02303327","Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients","2026-12","Androgen deprivation therapy",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT02685397","Management of Castration-Resistant Prostate Cancer with Oligometastases","2027-04","Leuprolide Acetate",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT07003880","Penthrox in Otolaryngology","2027-05-01","Methoxyflurane anesthesia",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT07371728","Effect of Aprepitant on Post-operative Nausea and Vomiting in Otologic Surgery","2027-06-01","Aprepitant",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT07254962","CApecitabine Prior to TUmor Resection in Ent Oncology (CAPTURE)","2028-01-01","Capecitabine",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT04150458","Fluorocholine PET\u002FCT Basket Trial","2030-01","18F-fluorocholine PET\u002FCT.",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT04070209","Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)","2030-11","Darolutamide",[80,81,82,83,84,85],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[87,112,138,156,174,192,213,236,260,281,304,329,349,376,401,425,452,470,496,520,543,568,595,613,639,664,690,713,741,766,791,818,843,868],{"intervention":63,"totalTrials":88,"cells":89},1,{"EARLY_PHASE1":90,"PHASE1":93,"PHASE2":95,"PHASE3":97,"PHASE4":99,"NA":110},{"trials":91,"activeCount":92},[],0,{"trials":94,"activeCount":92},[],{"trials":96,"activeCount":92},[],{"trials":98,"activeCount":92},[],{"trials":100,"activeCount":88,"soonestReadout":62},[101],{"nctId":60,"briefTitle":61,"status":102,"phases":103,"primaryCompletion":62,"completion":104,"start":105,"enrollment":106,"conditions":107,"interventions":109},"NOT_YET_RECRUITING",[84],"2028-06-01","2026-06-01",100,[108],"Otologic Disease",[63],{"trials":111,"activeCount":92},[],{"intervention":53,"totalTrials":88,"cells":113},{"EARLY_PHASE1":114,"PHASE1":116,"PHASE2":118,"PHASE3":120,"PHASE4":134,"NA":136},{"trials":115,"activeCount":92},[],{"trials":117,"activeCount":92},[],{"trials":119,"activeCount":92},[],{"trials":121,"activeCount":88,"soonestReadout":52},[122],{"nctId":50,"briefTitle":51,"status":123,"phases":124,"primaryCompletion":52,"completion":125,"start":126,"enrollment":127,"conditions":128,"interventions":130},"ACTIVE_NOT_RECRUITING",[82,83],"2041-08","2016-10",102,[129],"Castration-resistant Prostate Cancer Patients with Oligometastases",[53,131,132,133],"Goserelin Acetate","Triptorelin","Enzalutamide",{"trials":135,"activeCount":92},[],{"trials":137,"activeCount":92},[],{"intervention":131,"totalTrials":88,"cells":139},{"EARLY_PHASE1":140,"PHASE1":142,"PHASE2":144,"PHASE3":146,"PHASE4":152,"NA":154},{"trials":141,"activeCount":92},[],{"trials":143,"activeCount":92},[],{"trials":145,"activeCount":92},[],{"trials":147,"activeCount":88,"soonestReadout":52},[148],{"nctId":50,"briefTitle":51,"status":123,"phases":149,"primaryCompletion":52,"completion":125,"start":126,"enrollment":127,"conditions":150,"interventions":151},[82,83],[129],[53,131,132,133],{"trials":153,"activeCount":92},[],{"trials":155,"activeCount":92},[],{"intervention":132,"totalTrials":88,"cells":157},{"EARLY_PHASE1":158,"PHASE1":160,"PHASE2":162,"PHASE3":164,"PHASE4":170,"NA":172},{"trials":159,"activeCount":92},[],{"trials":161,"activeCount":92},[],{"trials":163,"activeCount":92},[],{"trials":165,"activeCount":88,"soonestReadout":52},[166],{"nctId":50,"briefTitle":51,"status":123,"phases":167,"primaryCompletion":52,"completion":125,"start":126,"enrollment":127,"conditions":168,"interventions":169},[82,83],[129],[53,131,132,133],{"trials":171,"activeCount":92},[],{"trials":173,"activeCount":92},[],{"intervention":133,"totalTrials":88,"cells":175},{"EARLY_PHASE1":176,"PHASE1":178,"PHASE2":180,"PHASE3":182,"PHASE4":188,"NA":190},{"trials":177,"activeCount":92},[],{"trials":179,"activeCount":92},[],{"trials":181,"activeCount":92},[],{"trials":183,"activeCount":88,"soonestReadout":52},[184],{"nctId":50,"briefTitle":51,"status":123,"phases":185,"primaryCompletion":52,"completion":125,"start":126,"enrollment":127,"conditions":186,"interventions":187},[82,83],[129],[53,131,132,133],{"trials":189,"activeCount":92},[],{"trials":191,"activeCount":92},[],{"intervention":48,"totalTrials":88,"cells":193},{"EARLY_PHASE1":194,"PHASE1":196,"PHASE2":198,"PHASE3":200,"PHASE4":209,"NA":211},{"trials":195,"activeCount":92},[],{"trials":197,"activeCount":92},[],{"trials":199,"activeCount":92},[],{"trials":201,"activeCount":88,"soonestReadout":47},[202],{"nctId":45,"briefTitle":46,"status":123,"phases":203,"primaryCompletion":47,"completion":204,"start":205,"enrollment":206,"conditions":207,"interventions":208},[83],"2029-01","2015-01",307,[15],[48],{"trials":210,"activeCount":92},[],{"trials":212,"activeCount":92},[],{"intervention":73,"totalTrials":88,"cells":214},{"EARLY_PHASE1":215,"PHASE1":217,"PHASE2":219,"PHASE3":221,"PHASE4":232,"NA":234},{"trials":216,"activeCount":92},[],{"trials":218,"activeCount":92},[],{"trials":220,"activeCount":92},[],{"trials":222,"activeCount":88,"soonestReadout":72},[223],{"nctId":70,"briefTitle":71,"status":224,"phases":225,"primaryCompletion":72,"completion":226,"start":227,"enrollment":228,"conditions":229,"interventions":231},"ENROLLING_BY_INVITATION",[83],"2030-07","2022-11-30",2000,[230],"Fluorocholine PET\u002FCT",[73],{"trials":233,"activeCount":92},[],{"trials":235,"activeCount":92},[],{"intervention":38,"totalTrials":88,"cells":237},{"EARLY_PHASE1":238,"PHASE1":240,"PHASE2":242,"PHASE3":244,"PHASE4":256,"NA":258},{"trials":239,"activeCount":92},[],{"trials":241,"activeCount":92},[],{"trials":243,"activeCount":92},[],{"trials":245,"activeCount":88,"soonestReadout":37},[246],{"nctId":35,"briefTitle":36,"status":247,"phases":248,"primaryCompletion":37,"completion":249,"start":250,"enrollment":251,"conditions":252,"interventions":255},"RECRUITING",[83],"2027-03-07","2023-02-02",798,[253,254],"Acute Coronary Syndrome","Cardiovascular Diseases",[38],{"trials":257,"activeCount":92},[],{"trials":259,"activeCount":92},[],{"intervention":78,"totalTrials":88,"cells":261},{"EARLY_PHASE1":262,"PHASE1":264,"PHASE2":266,"PHASE3":275,"PHASE4":277,"NA":279},{"trials":263,"activeCount":92},[],{"trials":265,"activeCount":92},[],{"trials":267,"activeCount":88,"soonestReadout":77},[268],{"nctId":75,"briefTitle":76,"status":123,"phases":269,"primaryCompletion":77,"completion":77,"start":270,"enrollment":271,"conditions":272,"interventions":274},[82],"2020-10-19",66,[30,273],"Castration-resistant Prostate Cancer",[78],{"trials":276,"activeCount":92},[],{"trials":278,"activeCount":92},[],{"trials":280,"activeCount":92},[],{"intervention":43,"totalTrials":88,"cells":282},{"EARLY_PHASE1":283,"PHASE1":285,"PHASE2":287,"PHASE3":298,"PHASE4":300,"NA":302},{"trials":284,"activeCount":92},[],{"trials":286,"activeCount":92},[],{"trials":288,"activeCount":88,"soonestReadout":42},[289],{"nctId":40,"briefTitle":41,"status":102,"phases":290,"primaryCompletion":42,"completion":291,"start":292,"enrollment":293,"conditions":294,"interventions":297},[82],"2027-12-01","2024-10-01",50,[295,296],"Head Neck Cancer","Xerostomia Following Radiotherapy",[43],{"trials":299,"activeCount":92},[],{"trials":301,"activeCount":92},[],{"trials":303,"activeCount":92},[],{"intervention":68,"totalTrials":88,"cells":305},{"EARLY_PHASE1":306,"PHASE1":308,"PHASE2":310,"PHASE3":323,"PHASE4":325,"NA":327},{"trials":307,"activeCount":92},[],{"trials":309,"activeCount":92},[],{"trials":311,"activeCount":88,"soonestReadout":67},[312],{"nctId":65,"briefTitle":66,"status":102,"phases":313,"primaryCompletion":67,"completion":314,"start":315,"enrollment":316,"conditions":317,"interventions":322},[82],"2031-01-01","2026-01-01",75,[295,318,319,320,321],"Mouth Cancer","Throat Cancer","Larynx Cancer","Skin Cancer Face",[68],{"trials":324,"activeCount":92},[],{"trials":326,"activeCount":92},[],{"trials":328,"activeCount":92},[],{"intervention":58,"totalTrials":88,"cells":330},{"EARLY_PHASE1":331,"PHASE1":333,"PHASE2":335,"PHASE3":337,"PHASE4":339,"NA":341},{"trials":332,"activeCount":92},[],{"trials":334,"activeCount":92},[],{"trials":336,"activeCount":92},[],{"trials":338,"activeCount":92},[],{"trials":340,"activeCount":92},[],{"trials":342,"activeCount":88,"soonestReadout":57},[343],{"nctId":55,"briefTitle":56,"status":102,"phases":344,"primaryCompletion":57,"completion":62,"start":345,"enrollment":293,"conditions":346,"interventions":348},[],"2025-06-01",[347],"All Adult Patients Undergoing an Otolaryngology Procedure With Inhaled Methoxyflurane as an Adjunct to Topical or Local Anesthesia",[58],{"intervention":350,"totalTrials":88,"cells":351},"Fesoterodine",{"EARLY_PHASE1":352,"PHASE1":354,"PHASE2":356,"PHASE3":358,"PHASE4":360,"NA":374},{"trials":353,"activeCount":92},[],{"trials":355,"activeCount":92},[],{"trials":357,"activeCount":92},[],{"trials":359,"activeCount":92},[],{"trials":361,"activeCount":92},[362],{"nctId":363,"briefTitle":364,"status":365,"phases":366,"primaryCompletion":367,"completion":367,"start":368,"enrollment":369,"conditions":370,"interventions":373},"NCT02385500","Fesoterodine on Urgency Episodes in Parkinson's Disease Population","TERMINATED",[84],"2019-06-07","2016-09",5,[371,372],"Urinary Bladder, Overactive","Parkinson Disease",[350],{"trials":375,"activeCount":92},[],{"intervention":377,"totalTrials":88,"cells":378},"18F-Fluoromethylcholine",{"EARLY_PHASE1":379,"PHASE1":381,"PHASE2":383,"PHASE3":385,"PHASE4":397,"NA":399},{"trials":380,"activeCount":92},[],{"trials":382,"activeCount":92},[],{"trials":384,"activeCount":92},[],{"trials":386,"activeCount":92},[387],{"nctId":388,"briefTitle":389,"status":390,"phases":391,"primaryCompletion":392,"completion":393,"start":368,"enrollment":394,"conditions":395,"interventions":396},"NCT02840552","The Safety and Efficacy of 18F-Fluoromethylcholine (18F-FCH) PET\u002FCT in Prostate Cancer","COMPLETED",[83],"2018-02","2018-03",60,[15],[377],{"trials":398,"activeCount":92},[],{"trials":400,"activeCount":92},[],{"intervention":402,"totalTrials":88,"cells":403},"68Ga-HBED-CC-PSMA PET\u002FCT",{"EARLY_PHASE1":404,"PHASE1":406,"PHASE2":408,"PHASE3":410,"PHASE4":421,"NA":423},{"trials":405,"activeCount":92},[],{"trials":407,"activeCount":92},[],{"trials":409,"activeCount":92},[],{"trials":411,"activeCount":92},[412],{"nctId":413,"briefTitle":414,"status":390,"phases":415,"primaryCompletion":416,"completion":416,"start":417,"enrollment":418,"conditions":419,"interventions":420},"NCT03001869","68Ga-PSMA PET\u002FCT in Prostate Cancer",[83],"2023-07-01","2017-07-01",540,[15],[402],{"trials":422,"activeCount":92},[],{"trials":424,"activeCount":92},[],{"intervention":426,"totalTrials":88,"cells":427},"Preventive administration of Rapaflo",{"EARLY_PHASE1":428,"PHASE1":430,"PHASE2":432,"PHASE3":434,"PHASE4":448,"NA":450},{"trials":429,"activeCount":92},[],{"trials":431,"activeCount":92},[],{"trials":433,"activeCount":92},[],{"trials":435,"activeCount":92},[436],{"nctId":437,"briefTitle":438,"status":390,"phases":439,"primaryCompletion":440,"completion":441,"start":442,"enrollment":443,"conditions":444,"interventions":446},"NCT02220829","Comparative Study of Use of Alpha-Blockers to Treat Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy",[83],"2023-04","2023-08","2016-06",148,[445,15],"Urinary Problems",[426,447],"Standard Care",{"trials":449,"activeCount":92},[],{"trials":451,"activeCount":92},[],{"intervention":447,"totalTrials":88,"cells":453},{"EARLY_PHASE1":454,"PHASE1":456,"PHASE2":458,"PHASE3":460,"PHASE4":466,"NA":468},{"trials":455,"activeCount":92},[],{"trials":457,"activeCount":92},[],{"trials":459,"activeCount":92},[],{"trials":461,"activeCount":92},[462],{"nctId":437,"briefTitle":438,"status":390,"phases":463,"primaryCompletion":440,"completion":441,"start":442,"enrollment":443,"conditions":464,"interventions":465},[83],[445,15],[426,447],{"trials":467,"activeCount":92},[],{"trials":469,"activeCount":92},[],{"intervention":471,"totalTrials":88,"cells":472},"Micronized Purified Flavonoid Fraction",{"EARLY_PHASE1":473,"PHASE1":475,"PHASE2":477,"PHASE3":479,"PHASE4":492,"NA":494},{"trials":474,"activeCount":92},[],{"trials":476,"activeCount":92},[],{"trials":478,"activeCount":92},[],{"trials":480,"activeCount":92},[481],{"nctId":482,"briefTitle":483,"status":484,"phases":485,"primaryCompletion":486,"completion":487,"start":488,"enrollment":489,"conditions":490,"interventions":491},"NCT03833024","The MUFFIN-PTS Trial","UNKNOWN",[83],"2024-03-30","2024-05-30","2022-02-04",88,[28],[471],{"trials":493,"activeCount":92},[],{"trials":495,"activeCount":92},[],{"intervention":497,"totalTrials":88,"cells":498},"antidepressant medications, flexible drug choice",{"EARLY_PHASE1":499,"PHASE1":501,"PHASE2":503,"PHASE3":505,"PHASE4":516,"NA":518},{"trials":500,"activeCount":92},[],{"trials":502,"activeCount":92},[],{"trials":504,"activeCount":92},[],{"trials":506,"activeCount":92},[507],{"nctId":508,"briefTitle":509,"status":484,"phases":510,"start":511,"enrollment":512,"conditions":513,"interventions":515},"NCT00220623","Efficacy of 18-Months of Antidepressive Medication Plus CBT or Dynamic or Supportive Psychotherapy for Recurrent Major Depression",[83],"2004-08",30,[514],"Major Depression",[497],{"trials":517,"activeCount":92},[],{"trials":519,"activeCount":92},[],{"intervention":521,"totalTrials":88,"cells":522},"18F-DCFPyL PET\u002FCT",{"EARLY_PHASE1":523,"PHASE1":525,"PHASE2":527,"PHASE3":537,"PHASE4":539,"NA":541},{"trials":524,"activeCount":92},[],{"trials":526,"activeCount":92},[],{"trials":528,"activeCount":92},[529],{"nctId":530,"briefTitle":531,"status":390,"phases":532,"primaryCompletion":533,"completion":533,"start":417,"enrollment":534,"conditions":535,"interventions":536},"NCT03001895","Correlation Between SUV on 18F-DCFPyL PET\u002FCT and Gleason Score in Prostate Cancer",[82],"2018-10-05",120,[15],[521],{"trials":538,"activeCount":92},[],{"trials":540,"activeCount":92},[],{"trials":542,"activeCount":92},[],{"intervention":544,"totalTrials":88,"cells":545},"radium-223 dichloride",{"EARLY_PHASE1":546,"PHASE1":548,"PHASE2":550,"PHASE3":562,"PHASE4":564,"NA":566},{"trials":547,"activeCount":92},[],{"trials":549,"activeCount":92},[],{"trials":551,"activeCount":92},[552],{"nctId":553,"briefTitle":554,"status":390,"phases":555,"primaryCompletion":556,"completion":557,"start":558,"enrollment":559,"conditions":560,"interventions":561},"NCT03062254","Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET\u002FCT Following Radium-223 Therapy",[82],"2020-07-15","2021-07-15","2018-03-22",14,[15],[544],{"trials":563,"activeCount":92},[],{"trials":565,"activeCount":92},[],{"trials":567,"activeCount":92},[],{"intervention":569,"totalTrials":88,"cells":570},"Aliskiren vs. hydrochlorothiazide",{"EARLY_PHASE1":571,"PHASE1":573,"PHASE2":575,"PHASE3":589,"PHASE4":591,"NA":593},{"trials":572,"activeCount":92},[],{"trials":574,"activeCount":92},[],{"trials":576,"activeCount":92},[577],{"nctId":578,"briefTitle":579,"status":580,"phases":581,"primaryCompletion":582,"completion":582,"start":583,"enrollment":92,"conditions":584,"interventions":587},"NCT01480791","Aliskiren vs Hydrochlorothiazide in Hypertensive Type II Diabetic Patients on Resistance Arteries","WITHDRAWN",[82],"2013-12","2012-01",[585,586],"Hypertension","Diabetes",[569,588],"Hydrochlorothiazide",{"trials":590,"activeCount":92},[],{"trials":592,"activeCount":92},[],{"trials":594,"activeCount":92},[],{"intervention":588,"totalTrials":88,"cells":596},{"EARLY_PHASE1":597,"PHASE1":599,"PHASE2":601,"PHASE3":607,"PHASE4":609,"NA":611},{"trials":598,"activeCount":92},[],{"trials":600,"activeCount":92},[],{"trials":602,"activeCount":92},[603],{"nctId":578,"briefTitle":579,"status":580,"phases":604,"primaryCompletion":582,"completion":582,"start":583,"enrollment":92,"conditions":605,"interventions":606},[82],[585,586],[569,588],{"trials":608,"activeCount":92},[],{"trials":610,"activeCount":92},[],{"trials":612,"activeCount":92},[],{"intervention":614,"totalTrials":88,"cells":615},"Pentosan Polysulfate Na 100Mg Cap",{"EARLY_PHASE1":616,"PHASE1":618,"PHASE2":620,"PHASE3":633,"PHASE4":635,"NA":637},{"trials":617,"activeCount":92},[],{"trials":619,"activeCount":92},[],{"trials":621,"activeCount":92},[622],{"nctId":623,"briefTitle":624,"status":365,"phases":625,"primaryCompletion":626,"completion":626,"start":627,"enrollment":19,"conditions":628,"interventions":632},"NCT03549650","Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms",[82],"2022-02-15","2019-05-03",[629,630,631],"Lower Urinary Tract Symptoms","Bladder Carcinoma","BCG",[614],{"trials":634,"activeCount":92},[],{"trials":636,"activeCount":92},[],{"trials":638,"activeCount":92},[],{"intervention":640,"totalTrials":88,"cells":641},"hydroxychloroquine sulfate 200 MG",{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":658,"PHASE4":660,"NA":662},{"trials":643,"activeCount":92},[],{"trials":645,"activeCount":92},[],{"trials":647,"activeCount":92},[648],{"nctId":649,"briefTitle":650,"status":580,"phases":651,"primaryCompletion":652,"completion":652,"start":652,"enrollment":92,"conditions":653,"interventions":657},"NCT04354441","Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women",[82],"2020-05",[32,654,655,656],"SARS-CoV-2","Pregnant Women","Hydroxychloroquine",[640],{"trials":659,"activeCount":92},[],{"trials":661,"activeCount":92},[],{"trials":663,"activeCount":92},[],{"intervention":665,"totalTrials":88,"cells":666},"Progesterone",{"EARLY_PHASE1":667,"PHASE1":669,"PHASE2":671,"PHASE3":684,"PHASE4":686,"NA":688},{"trials":668,"activeCount":92},[],{"trials":670,"activeCount":92},[],{"trials":672,"activeCount":92},[673],{"nctId":674,"briefTitle":675,"status":390,"phases":676,"primaryCompletion":677,"completion":677,"start":678,"enrollment":679,"conditions":680,"interventions":683},"NCT02145767","Progesterone for the Prevention of Miscarriage and Preterm Birth in Women With First Trimester Bleeding: PREEMPT Trial",[82],"2021-02","2014-12",850,[681,682],"Miscarriage","Preterm Birth",[665],{"trials":685,"activeCount":92},[],{"trials":687,"activeCount":92},[],{"trials":689,"activeCount":92},[],{"intervention":691,"totalTrials":88,"cells":692},"68Ga-HBED-CC-PSMA (DKFZ-11) PET\u002FCT",{"EARLY_PHASE1":693,"PHASE1":695,"PHASE2":697,"PHASE3":707,"PHASE4":709,"NA":711},{"trials":694,"activeCount":92},[],{"trials":696,"activeCount":92},[],{"trials":698,"activeCount":92},[699],{"nctId":700,"briefTitle":701,"status":390,"phases":702,"primaryCompletion":703,"completion":703,"start":704,"enrollment":489,"conditions":705,"interventions":706},"NCT02796807","Correlation Between SUV on 68Ga-HBED-CC-PSMA and Gleason Score in Prostate Cancer",[82],"2017-12","2016-05",[15],[691],{"trials":708,"activeCount":92},[],{"trials":710,"activeCount":92},[],{"trials":712,"activeCount":92},[],{"intervention":714,"totalTrials":88,"cells":715},"131I-PSMA-1095 Radioligand Therapy",{"EARLY_PHASE1":716,"PHASE1":718,"PHASE2":720,"PHASE3":735,"PHASE4":737,"NA":739},{"trials":717,"activeCount":92},[],{"trials":719,"activeCount":92},[],{"trials":721,"activeCount":92},[722],{"nctId":723,"briefTitle":724,"status":365,"phases":725,"primaryCompletion":726,"completion":726,"start":727,"enrollment":728,"conditions":729,"interventions":734},"NCT04085991","Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer",[82],"2023-01-15","2020-07-31",11,[15,730,731,30,732,733],"Prostate Adenocarcinoma","Prostatic Neoplasms","Metastatic Prostatic Adenocarcinoma","Metastatic Prostate Carcinoma in the Soft Tissue",[714],{"trials":736,"activeCount":92},[],{"trials":738,"activeCount":92},[],{"trials":740,"activeCount":92},[],{"intervention":742,"totalTrials":88,"cells":743},"losartan, hydrochlorothiazide",{"EARLY_PHASE1":744,"PHASE1":746,"PHASE2":748,"PHASE3":760,"PHASE4":762,"NA":764},{"trials":745,"activeCount":92},[],{"trials":747,"activeCount":92},[],{"trials":749,"activeCount":92},[750],{"nctId":751,"briefTitle":752,"status":365,"phases":753,"primaryCompletion":754,"completion":754,"start":755,"enrollment":88,"conditions":756,"interventions":759},"NCT00388388","Losartan Versus Hydrochlorothiazide in Reversing Remodeling of Small Arteries in Pre-Hypertensive Pre-Diabetic Subjects",[82],"2009-12","2007-03",[757,758],"Pre-hypertension","Pre-diabetes",[742],{"trials":761,"activeCount":92},[],{"trials":763,"activeCount":92},[],{"trials":765,"activeCount":92},[],{"intervention":767,"totalTrials":88,"cells":768},"FOLFOX",{"EARLY_PHASE1":769,"PHASE1":771,"PHASE2":773,"PHASE3":785,"PHASE4":787,"NA":789},{"trials":770,"activeCount":92},[],{"trials":772,"activeCount":92},[],{"trials":774,"activeCount":92},[775],{"nctId":776,"briefTitle":777,"status":390,"phases":778,"primaryCompletion":779,"completion":779,"start":780,"enrollment":781,"conditions":782,"interventions":784},"NCT01274962","A Study on the Timing of FOLFOX for Patients With Operable, Node Positive Rectal Cancer",[82],"2022-12","2009-11",180,[783],"Operable T2-3N+M0 Rectal Cancer (Stage III)",[767],{"trials":786,"activeCount":92},[],{"trials":788,"activeCount":92},[],{"trials":790,"activeCount":92},[],{"intervention":792,"totalTrials":88,"cells":793},"Niraparib oral",{"EARLY_PHASE1":794,"PHASE1":808,"PHASE2":810,"PHASE3":812,"PHASE4":814,"NA":816},{"trials":795,"activeCount":92},[796],{"nctId":797,"briefTitle":798,"status":580,"phases":799,"primaryCompletion":800,"completion":801,"start":802,"enrollment":92,"conditions":803,"interventions":807},"NCT05289648","Niraparib in High-grade Endometrial Cancer Trial",[80],"2025-10-31","2026-01-31","2024-05-01",[804,805,806],"Endometrial Cancer","Serous Adenocarcinoma","Uterine Neoplasm",[792],{"trials":809,"activeCount":92},[],{"trials":811,"activeCount":92},[],{"trials":813,"activeCount":92},[],{"trials":815,"activeCount":92},[],{"trials":817,"activeCount":92},[],{"intervention":819,"totalTrials":88,"cells":820},"Transdermal nicotine patch",{"EARLY_PHASE1":821,"PHASE1":823,"PHASE2":825,"PHASE3":827,"PHASE4":829,"NA":831},{"trials":822,"activeCount":92},[],{"trials":824,"activeCount":92},[],{"trials":826,"activeCount":92},[],{"trials":828,"activeCount":92},[],{"trials":830,"activeCount":92},[],{"trials":832,"activeCount":92},[833],{"nctId":834,"briefTitle":835,"status":836,"phases":837,"primaryCompletion":838,"completion":754,"start":839,"enrollment":512,"conditions":840,"interventions":842},"NCT00990197","The Safety of Transdermal Nicotine Immediately Following an Acute Coronary Syndrome","SUSPENDED",[85],"2009-07","2005-06",[841],"Smoking Cessation",[819],{"intervention":844,"totalTrials":88,"cells":845},"18F-Fluorocholine PET\u002FCT",{"EARLY_PHASE1":846,"PHASE1":848,"PHASE2":850,"PHASE3":852,"PHASE4":854,"NA":856},{"trials":847,"activeCount":92},[],{"trials":849,"activeCount":92},[],{"trials":851,"activeCount":92},[],{"trials":853,"activeCount":92},[],{"trials":855,"activeCount":92},[],{"trials":857,"activeCount":92},[858],{"nctId":859,"briefTitle":860,"status":390,"phases":861,"primaryCompletion":862,"completion":863,"start":864,"enrollment":865,"conditions":866,"interventions":867},"NCT02793882","Correlation Between SUV on 18F-Fluorocholine PET\u002FCT and Gleason Score in Prostate Cancer",[],"2017-03-25","2017-04-24","2013-09",218,[15],[844],{"intervention":869,"totalTrials":88,"cells":870},"LHRH therapy",{"EARLY_PHASE1":871,"PHASE1":873,"PHASE2":875,"PHASE3":877,"PHASE4":879,"NA":881},{"trials":872,"activeCount":92},[],{"trials":874,"activeCount":92},[],{"trials":876,"activeCount":92},[],{"trials":878,"activeCount":92},[],{"trials":880,"activeCount":92},[],{"trials":882,"activeCount":92},[883],{"nctId":884,"briefTitle":885,"status":580,"phases":886,"primaryCompletion":72,"completion":72,"start":887,"enrollment":92,"conditions":888,"interventions":889},"NCT02588404","The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient",[],"2015-12",[15],[869]]